Cargando…
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
The major determinant of the decline in lung function, quality of life, and the increased mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, that is, those requiring patients’ hospitalization, constituting a substantial social and health care burden in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072677/ https://www.ncbi.nlm.nih.gov/pubmed/30104872 http://dx.doi.org/10.2147/COPD.S147484 |
_version_ | 1783344035305357312 |
---|---|
author | Mantero, Marco Radovanovic, Dejan Santus, Pierachille Blasi, Francesco |
author_facet | Mantero, Marco Radovanovic, Dejan Santus, Pierachille Blasi, Francesco |
author_sort | Mantero, Marco |
collection | PubMed |
description | The major determinant of the decline in lung function, quality of life, and the increased mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, that is, those requiring patients’ hospitalization, constituting a substantial social and health care burden in terms of morbidity and medical resource utilization. Different long-term therapeutic strategies have been proposed so far in order to prevent and/or reduce the clinical and social impact of these events, the majority of which were extrapolated from trials initially focused on the effect of long-acting muscarinic antagonist and subsequently on the efficacy of long-acting β2-agonists in combination or not with inhaled corticosteroids. The option to employ all three classes of molecules combined, despite the limited amount of evidence in our possession, represents a choice currently proposed by international guidelines; however, current recommendations are often based mainly on observational studies or on the results of secondary outcomes in randomized controlled trials. The present narrative review evaluates the available trials that investigated the efficacy of inhaled therapy to prevent COPD exacerbations and especially severe ones, with a particular focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed dose combination, which is the first treatment that comprises all the three drug classes, specifically tested for the prevention of moderate and severe COPD exacerbations. |
format | Online Article Text |
id | pubmed-6072677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60726772018-08-13 Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide Mantero, Marco Radovanovic, Dejan Santus, Pierachille Blasi, Francesco Int J Chron Obstruct Pulmon Dis Review The major determinant of the decline in lung function, quality of life, and the increased mortality risk in patients with COPD is represented by severe acute exacerbations of the disease, that is, those requiring patients’ hospitalization, constituting a substantial social and health care burden in terms of morbidity and medical resource utilization. Different long-term therapeutic strategies have been proposed so far in order to prevent and/or reduce the clinical and social impact of these events, the majority of which were extrapolated from trials initially focused on the effect of long-acting muscarinic antagonist and subsequently on the efficacy of long-acting β2-agonists in combination or not with inhaled corticosteroids. The option to employ all three classes of molecules combined, despite the limited amount of evidence in our possession, represents a choice currently proposed by international guidelines; however, current recommendations are often based mainly on observational studies or on the results of secondary outcomes in randomized controlled trials. The present narrative review evaluates the available trials that investigated the efficacy of inhaled therapy to prevent COPD exacerbations and especially severe ones, with a particular focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide fixed dose combination, which is the first treatment that comprises all the three drug classes, specifically tested for the prevention of moderate and severe COPD exacerbations. Dove Medical Press 2018-07-30 /pmc/articles/PMC6072677/ /pubmed/30104872 http://dx.doi.org/10.2147/COPD.S147484 Text en © 2018 Mantero et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Mantero, Marco Radovanovic, Dejan Santus, Pierachille Blasi, Francesco Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide |
title | Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide |
title_full | Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide |
title_fullStr | Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide |
title_full_unstemmed | Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide |
title_short | Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide |
title_sort | management of severe copd exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072677/ https://www.ncbi.nlm.nih.gov/pubmed/30104872 http://dx.doi.org/10.2147/COPD.S147484 |
work_keys_str_mv | AT manteromarco managementofseverecopdexacerbationsfocusonbeclomethasonedipropionateformoterolglycopyrroniumbromide AT radovanovicdejan managementofseverecopdexacerbationsfocusonbeclomethasonedipropionateformoterolglycopyrroniumbromide AT santuspierachille managementofseverecopdexacerbationsfocusonbeclomethasonedipropionateformoterolglycopyrroniumbromide AT blasifrancesco managementofseverecopdexacerbationsfocusonbeclomethasonedipropionateformoterolglycopyrroniumbromide |